Introduction: Colorectal cancer (CRC) is the most incident in Spain, according to Spanish Network of Cancer Registries (REDECAN) and is the second cause of death by cancer in Spain. Although the OS in metastatic setting has increased to 24-30 months, the 5-year OS continues to be less than 12%. The first and second line of treatment are well defined; however, there are few therapeutic options for those patients who have progressed to these standard therapies. After progression to the second line of treatment, the only therapeutic options with approved specific indication are Regorafenib and Trifluridine and Tipiracil. Trifluridine and Tipiracil has shown its efficacy in two randomized clinical trials comparing Trifluridine and Tipiracil versus placebo: a Phase II and a Phase III study (RECOURSE). In the previous Phase II study, the mOS was 9.0 months in the group treated with Trifluridine and Tipiracil, compared to 6.6 months in the placebo group. In the RECOURSE study, among patients treated with Trifluridine and Tipiracil mPFS was 2 months versus 1.7 months among those treated with placebo, and mOS was 10,5 with Trifluridine and Tipiracil vs 7,6 with placebo. We described the clinical characteristic of patients treated with Trifluridine and Tipiracil in seven hospitals from Madrid; identifying and analyzing clinical factors associated with long-term response. Methods: We collected retrospectively the clinical data of 98 patients who had received treatment with Trifluridine and Tipiracil until January 2018 in seven different hospitals in Madrid. Results: The mean age at first use of Trifluridine and Tipiracil was 666 9.45 years, 57.5% were men and 42.3% were women, most of them in good performance status P À 268 Advanced colorectal cancer and risk factors for survival
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.